Specialty Drugs and Upcoding Drive Rising Medical Costs, Pressure U.S. Health Insurers
Major U.S. health insurers face rising medical costs driven by specialty drug spending and upcoding, impacting earnings and Medicaid, ACA market dynamics in 2025.
U.S. Sees 25% Rise in Drug Denials; Sarepta Gene Therapy Deaths; Medicaid Data Access for ICE
Prescription drug denials by private insurers rise 25% (2016-2023). Sarepta gene therapy linked to patient deaths. ICE gains Medicaid data access. ACA insurers seek 2026 rate hikes. Implications for U.S. insurance, regulatory compliance, and patient access.